Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).
Authors
Stephen Lam Chan
State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China
Stephen Lam Chan , Ahmed Omar Kaseb , Wei Shi , Laura Alexander , Xianzhang Meng , CheolHee Park , Kristin Ryan , Arndt Vogel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03764293
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 456)
DOI
10.1200/JCO.2024.42.3_suppl.456
Abstract #
456
Poster Bd #
B1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
First Author: Arndt Vogel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
First Author: Feng Wen
Poster
2023 ASCO Breakthrough
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
First Author: Richard S. Finn
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
First Author: Richard S. Finn